Clinical Trial

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Recruiting Phase 1/2

Summary

This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2020-12-23; most recent amendment 2026-01-08.

Status change: Not Yet Recruiting → Recruiting 2021-07-21

Trial Details

NCT Number	NCT04686682
Lead Sponsor	Jacobio Pharmaceuticals Co., Ltd.
Conditions	NSCLC, SCLC, CRPC, ESCC, Ovarian Carcinoma, AML, MF, Malignant Tumor
Enrollment	152 participants
Start Date	2021-05-07
Primary Completion	2028-01 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-01-09